Patents by Inventor Xiaohui GAO

Xiaohui GAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11547071
    Abstract: A method for disinfecting explants of Kadsura coccinea stems with buds and a method for directly inducing rapid proliferation of sterile buds by using the explants of Kadsura coccinea stems with buds involve processes such as selection, treatment and disinfection of explants, primary culture, subculture proliferation culture. The problem of difficulty in tissue culture and primary culture of Kadsura coccinea stems is solved, and the advantages include low contamination rate of explants, high propagation rate and robust proliferation of axillary buds. This allows obtaining sterile axillary buds of Kadsura coccinea through tissue culture, and provides support for tissue culture, rapid propagation and factory seedling of Kadsura coccinea in the future.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: January 10, 2023
    Assignee: CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY
    Inventors: Ze Li, Yang Liu, Hui Zhang, Xiaoqin Zhang, Xiaohui Gao, Fangfang Ma, Jiayue Zhong, Xiaoyan Zhang, Sen Wang, Xiaofeng Tan, Ao Yang, Fen Bao, Ruonan Ma
  • Patent number: 11306085
    Abstract: The present invention relates to a method for preparing a pyrimidone heteroaryl derivative and an intermediate of the pyrimidone heteroaryl derivative. Specifically, the pyrimidone heteroaryl derivative of the formula is prepared by changing a starting raw material and an intermediate.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: April 19, 2022
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Junlei Jia, Bing Liu, Xiaohui Gao
  • Publication number: 20220007606
    Abstract: A method for disinfecting explants of Kadsura coccinea stems with buds and a method for directly inducing rapid proliferation of sterile buds by using the explants of Kadsura coccinea stems with buds involve processes such as selection, treatment and disinfection of explants, primary culture, subculture proliferation culture. The problem of difficulty in tissue culture and primary culture of Kadsura coccinea stems is solved, and the advantages include low contamination rate of explants, high propagation rate and robust proliferation of axillary buds. This allows obtaining sterile axillary buds of Kadsura coccinea through tissue culture, and provides support for tissue culture, rapid propagation and factory seedling of Kadsura coccinea in the future.
    Type: Application
    Filed: June 4, 2020
    Publication date: January 13, 2022
    Applicant: CENTRAL SOUTH UNIVERSITY OF FORESTRY AND TECHNOLOGY
    Inventors: Ze LI, Yang LIU, Hui ZHANG, Xiaoqin ZHANG, Xiaohui GAO, Fangfang MA, Jiayue ZHONG, Xiaoyan ZHANG, Sen WANG, Xiaofeng TAN, Ao YANG, Fen BAO, Ruonan MA
  • Patent number: 11083257
    Abstract: A deformable crutch, includes a hand-held part, a seat part and a support part which are rotatably connected in sequence, and further includes a locking device for locking a rotation angle between the hand-held part and the seat part, and a rotation angle between the seat part and the support part. Rollers (34) are provided at the bottom of the deformed stool. A motor for driving the rollers (34) can also be mounted to deform the deformable crutch into an electric scooter.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: August 10, 2021
    Inventor: Xiaohui Gao
  • Publication number: 20210024521
    Abstract: Disclosed are an intermediate of a pyrrolo six-membered heteroaromatic ring derivative as a JAK inhibitor and a preparation method therefor, and a method for preparing a pyrrolo six-membered heteroaromatic ring derivative using the intermediate. The method improves the reaction yield, is simple and easy to operate and control, and is conducive to expanded industrial production.
    Type: Application
    Filed: October 15, 2020
    Publication date: January 28, 2021
    Inventors: Bing Liu, Lin Bian, Xiaohui Gao
  • Publication number: 20210003566
    Abstract: A method for preparing a label-free aptamer electrochemical sensor of ?-interferon based on a dendrimer/gold nanoparticle/molybdenum disulfide nanocomposite is provided. The nanocomposite is drip-coated on a surface of an electrode to prepare a modified electrode, and a terminal sulfhydryl group of a ?-interferon aptamer chain is connected to the gold nanoparticle via Au—S bond to obtain a nanocomposite-aptamer modified electrode. When ?-interferon is present, the ?-interferon specifically binds to the aptamer chain on the sensor, resulting in the aptamer's hairpin structure being opened and stretched, which can effectively adsorb methylene blue MB in the electrolyte, causing significant enhancement of MB redox signal. A linear relationship between a current intensity of MB oxidation peak and a concentration of the ?-interferon is fitted to construct the label-free aptamer electrochemical sensor of ?-interferon.
    Type: Application
    Filed: March 21, 2019
    Publication date: January 7, 2021
    Applicant: Qingdao University
    Inventors: Hui JIN, Xiaohui GAO, Rijun GUI, Zonghua WANG
  • Patent number: 10883984
    Abstract: A method for preparing a label-free aptamer electrochemical sensor of ?-interferon based on a dendrimer/gold nanoparticle/molybdenum disulfide nanocomposite is provided. The nanocomposite is drip-coated on a surface of an electrode to prepare a modified electrode, and a terminal sulfhydryl group of a ?-interferon aptamer chain is connected to the gold nanoparticle via Au—S bond to obtain a nanocomposite-aptamer modified electrode. When ?-interferon is present, the ?-interferon specifically binds to the aptamer chain on the sensor, resulting in the aptamer's hairpin structure being opened and stretched, which can effectively adsorb methylene blue MB in the electrolyte, causing significant enhancement of MB redox signal. A linear relationship between a current intensity of MB oxidation peak and a concentration of the ?-interferon is fitted to construct the label-free aptamer electrochemical sensor of ?-interferon.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: January 5, 2021
    Assignee: QINGDAO UNIVERSITY
    Inventors: Hui Jin, Xiaohui Gao, Rijun Gui, Zonghua Wang
  • Patent number: 10851100
    Abstract: Disclosed are an intermediate of a pyrrolo six-membered heteroaromatic ring derivative as a JAK inhibitor and a preparation method therefor, and a method for preparing a pyrrolo six-membered heteroaromatic ring derivative using the intermediate. The method improves the reaction yield, is simple and easy to operate and control, and is conducive to expanded industrial production.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: December 1, 2020
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Bing Liu, Lin Bian, Xiaohui Gao
  • Patent number: 10787451
    Abstract: Provided are a crystalline form of a GnRH receptor antagonist and a preparation method therefor. Specifically, provided are a crystalline form I of 1-(4-(7-(2,6-difluorobenzyl)-3-((dimethylamino)methyl)-5-(6-methoxypyridazin-3-yl)-4,6-dicarbonyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)phenyl)-3-methoxy urea (a compound of formula I) and a preparation method, the use of same in a pharmaceutical composition and the use of the crystalline form I and the composition in the preparation of a drug for treating diseases associated with a GnRH receptor antagonist.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: September 29, 2020
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Suncadia Pharmaceuticals Co., Ltd.
    Inventors: Quanliang Zhang, Junlei Jia, Lin Bian, Xiaohui Gao
  • Publication number: 20200140434
    Abstract: The present invention relates to a method for preparing a pyrimidone heteroaryl derivative and an intermediate of the pyrimidone heteroaryl derivative. Specifically, in the present invention, the pyrimidone heteroaryl derivative is prepared by changing a starting raw material and an intermediate. The method shortens reaction steps, improves the reaction yield, is easy to operate and facilitates the expansion of industrial production.
    Type: Application
    Filed: July 27, 2018
    Publication date: May 7, 2020
    Inventors: Junlei JIA, Bing LIU, Xiaohui GAO
  • Publication number: 20200138153
    Abstract: A deformable crutch, includes a hand-held part, a seat part and a support part which are rotatably connected in sequence, and further includes a locking device for locking a rotation angle between the hand-held part and the seat part, and a rotation angle between the seat part and the support part. Rollers (34) are provided at the bottom of the deformed stool. A motor for driving the rollers (34) can also be mounted to deform the deformable crutch into an electric scooter.
    Type: Application
    Filed: February 1, 2018
    Publication date: May 7, 2020
    Inventor: Xiaohui GAO
  • Patent number: 10603047
    Abstract: A system for cutting a bone of a patient may include a motor; a rotating shaft drivingly coupled to the motor; a support tube positioned around the rotating shaft and supporting the rotating shaft at a plurality of locations; a plurality of steering wires coupled to the support tube; and a bone cutter at a distal end of the rotating shaft.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: March 31, 2020
    Assignee: MAKO Surgical Corp.
    Inventors: Jienan Ding, Xiaohui Gao, Hyosig Kang
  • Publication number: 20190308972
    Abstract: Disclosed are an intermediate of a pyrrolo six-membered heteroaromatic ring derivative as a JAK inhibitor and a preparation method therefor, and a method for preparing a pyrrolo six-membered heteroaromatic ring derivative using the intermediate. The method improves the reaction yield, is simple and easy to operate and control, and is conducive to expanded industrial production.
    Type: Application
    Filed: November 22, 2017
    Publication date: October 10, 2019
    Inventors: Bing Liu, Lin Bian, Xiaohui Gao
  • Publication number: 20190276455
    Abstract: Provided are a crystalline form of a GnRH receptor antagonist and a preparation method therefor. Specifically, provided are a crystalline form I of 1-(4-(7-(2,6-difluorobenzyl)-3-((dimethylamino)methyl)-5-(6-methoxypyridazin-3-yl)-4,6-dicarbonyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)phenyl)-3-methoxy urea (a compound of formula I) and a preparation method, the use of same in a pharmaceutical composition and the use of the crystalline form I and the composition in the preparation of a drug for treating diseases associated with a GnRH receptor antagonist.
    Type: Application
    Filed: November 13, 2017
    Publication date: September 12, 2019
    Inventors: Quanliang ZHANG, Junlei JIA, Lin BIAN, Xiaohui GAO
  • Publication number: 20180370948
    Abstract: Disclosed are a p-toluenesulfonate of a MEK kinase inhibitor, and a crystal form thereof and a preparation method thereof. Specifically disclosed are a 2-((2-fluorine-4-iodophenyl)amino)-1-methyl-4-((6-methylpyridine-3-group)oxygroup)-6-carbonyl-1,6-dihydropyridine-3-formamide p-toluenesulfonate (a compound represented by formula (I)), a crystal form I, and a preparation method thereof. The obtained crystal form I of the compound of formula (I) has good crystal form stability and chemical stability, and the crystallization solvent used has low toxicity and low residue, and is more suitable for use in clinical treatment.
    Type: Application
    Filed: September 10, 2018
    Publication date: December 27, 2018
    Inventors: Guaili WU, Xiaohui GAO, Lin BIAN, Junlei JIA
  • Patent number: 10160759
    Abstract: Provided are a hydroxyethyl sulfonate of a cyclin-dependent protein kinase inhibitor, a crystalline form thereof and a preparation method therefor. Specifically, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperidin-4-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one hydroxyethyl sulfonate (compound of formula (I)), a crystal form I thereof and a preparation method therefor are provided. Crystal form I of the compound of formula (I) has good chemical and crystalline stability, low toxicity, and low residual crystallization solvent. The compound of formula (I) and crystal form I thereof can be used in improved clinical therapy.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: December 25, 2018
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Guaili Wu, Xiaohui Gao, Junlei Jia
  • Patent number: 10150770
    Abstract: A crystal form I of a Janus Kinase (JAK) inhibitor (3aR,5s,6aS)—N-(3-methoxyl-1,2,4-thiadiazole-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidine-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-formamide bisulfate of formula (I) is provided. Also provided is a method of preparing the crystal form I of the JAK inhibitor of formula (I). The preparation method includes crystallizing any crystal form or amorphous compound solid of formula (I) in a single organic solvent to obtain the form I crystal. The crystal form I has excellent crystal stability and chemical stability. Additionally, the crystal solvent used to produce the crystal form I has low toxicity and a relatively low content of residual solvent, making the compound better suited for clinical treatment.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: December 11, 2018
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Piaoyang Sun, Guaili Wu, Xiaohui Gao, Yongjiang Chen, Lingjia Shen
  • Patent number: 10118911
    Abstract: Disclosed are a p-toluenesulfonate of a MEK kinase inhibitor, and a crystal form thereof and a preparation method thereof. Specifically disclosed are a 2-((2-fluorine-4-iodophenyl)amino)-1-methyl-4-((6-methylpyridine-3-group)oxygroup)-6-carbonyl-1,6-dihydropyridine-3-formamide p-toluenesulfonate (a compound represented by formula (I)), a crystal form I, and a preparation method thereof. The obtained crystal form I of the compound of formula (I) has good crystal form stability and chemical stability, and the crystallization solvent used has low toxicity and low residue, and is more suitable for use in clinical treatment.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: November 6, 2018
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Guaili Wu, Xiaohui Gao, Lin Bian, Junlei Jia
  • Publication number: 20180237438
    Abstract: A crystal form I of a Janus Kinase (JAK) inhibitor (3aR,5s,6aS)-N-(3-methoxyl-1,2,4-thiadiazole-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidine-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-formamide bisulfate of formula (I) is provided. Also provided is a method of preparing the crystal form I of the JAK inhibitor of formula (I). The preparation method includes crystallizing any crystal form or amorphous compound solid of formula (I) in a single organic solvent to obtain the form I crystal. The crystal form I has excellent crystal stability and chemical stability. Additionally, the crystal solvent used to produce the crystal form I has low toxicity and a relatively low content of residual solvent, making the compound better suited for clinical treatment.
    Type: Application
    Filed: September 9, 2015
    Publication date: August 23, 2018
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Piaoyang SUN, Guaili WU, Xiaohui GAO, Yongjiang CHEN, Lingjia SHEN
  • Patent number: D1057389
    Type: Grant
    Filed: June 20, 2022
    Date of Patent: January 14, 2025
    Inventor: Xiaohui Gao